All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Do the results of the LYSA LNH 09-1B trial support a PET-adapted treatment strategy for DLBCL?

During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Hervé Tilly, Centre Henri-Becquerel, Rouen, FR. We asked, Do the results of the LYSA LNH 09-1B trial support a positron emission tomography (PET)-adapted treatment strategy for DLBCL?

Do the results of the LYSA LNH 09-1B trial support a PET-adapted treatment strategy for DLBCL?

Tilly begins by describing the recently published PET-adapted approach, looking at whether four cycles of R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) were non-inferior to six cycles of R-CHOP. He highlights the major findings and ongoing analyzes from this study.

 

Share: